Examples of 'certolizumab' in a sentence
Meaning of "certolizumab"
When 'certolizumab' is used as an adjective, it typically describes medications or treatments related to Certolizumab, a drug used to treat certain autoimmune diseases
Show more definitions
- A particular monoclonal antibody used in the treatment of Crohn's disease.
How to use "certolizumab" in a sentence
Basic
Advanced
certolizumab
It contains the active substance certolizumab pegol.
Certolizumab is not available in generic forms.
The active substance is certolizumab pegol.
Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha.
There was no effect of gender on the pharmacokinetics of certolizumab pegol.
Certolizumab pegol works by stopping TNF alpha from acting on these receptors.
Cimzia contains the active substance certolizumab pegol.
Certolizumab pegol plasma concentrations were broadly dose-proportional.
Carcinogenicity studies have not been performed with certolizumab pegol.
The presence of antibodies to certolizumab pegol resulted in an approximately three-fold increase in clearance.
Treatment for latent infection should be initiated prior to certolizumab use.
Cimzia contains the active substance certolizumab pegol, a human antibody fragment.
Cimzia is a solution for injection that contains the active substance certolizumab pegol.
The clinical significance of low levels certolizumab pegol for infants is unknown.
Certolizumab pegol does not cross-react with rodent TNF.
See also
Pre-filled syringe with needle guard certolizumab pegol.
Due to its long half-life, certolizumab pegol can be administered subcutaneously once a month.
Other monoclonal antibodies targeting TNF-α are golimumab, adalimumab, and certolizumab pegol.
By blocking TNF-alpha, certolizumab pegol reduces inflammation and other symptoms of the diseases.
Additional examples include anti-TNF antibodies, such as adalimumab, certolizumab pegol, etanercept, and infliximab.
The combination of certolizumab pegol and anakinra or abatacept is not recommended see section 4.4.
Cimzia 200 mg solution for injection in pre-filled syringe Pre-filled syringe with needle guard certolizumab pegol.
The active substance in CIMZIA, certolizumab pegol, is an immunosuppressant medicine.
Certolizumab pegol does not bind to the human neonatal Fc receptor ( FcRn ).
The main anti-TNF antibodies that are currently authorized encompass Infliximab, Etanercept, Adalimumab, Certolizumab and Golimumab.
In CIMZIA, certolizumab has been ‘ pegylated ' attached to a chemical called polyethylene glycol.
One pre-filled syringe contains 200 mg certolizumab pegol in one ml.
Cimzia 200 mg solution for injection in dose-dispenser cartridge certolizumab pegol.
Each pre-filled pen contains 200 mg certolizumab pegol in one ml.
Cimzia 200 mg solution for injection in pre-filled syringe certolizumab pegol.
Following subcutaneous administration, peak plasma concentrations of certolizumab pegol were attained between 54 and 171 hours post-injection.
Cimzia 200 mg solution for injection in pre-filled pen certolizumab pegol.
Each pre-filled syringe contains 200 mg of certolizumab pegol in one ml.
In January 2012, UCB Japan filed an application for marketing approval for certolizumab pegol in Japan.
In embodiments, the TNF-a inhibitor is infliximab, adalimumab, certolizumab pegol, golimumab or etanercept.
Each dose-dispenser cartridge contains 200 mg of certolizumab pegol in one ml.
International non-proprietary name ( INN ), certolizumab pegol.
